Aristomenis P. Kotsakis

Patra, ESYE23, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A Validation Study of the COPSOQ III Greek Questionnaire for Assessing Psychosocial Factors in the Workplace.

A Validation Study of the COPSOQ III Greek Questionnaire for Assessing Psychosocial Factors in the Workplace.

Journal: Healthcare (Basel, Switzerland)

Published: June 22, 2025

Psychosocial risks and musculoskeletal disorders (MSD's) nurses face in the hospital working environment.

Psychosocial risks and musculoskeletal disorders (MSD's) nurses face in the hospital working environment.

Journal: Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

Published: March 10, 2025

Examining psychosocial risks and their impact on nurses' safety attitudes and medication error rates: A cross-sectional study.

Examining psychosocial risks and their impact on nurses' safety attitudes and medication error rates: A cross-sectional study.

Journal: AIMS public health

Published: October 16, 2024

THE RELATIONSHIP BETWEEN PSYCHOSOCIAL WORK ENVIRONMENT AND NURSES' PERFORMANCE, ON STUDIES THAT USED THE VALIDATED INSTRUMENT COPENHAGEN PSYCHOSOCIAL QUESTIONNAIRE (COPSOQ): AN EMPTY SCOPING REVIEW.

THE RELATIONSHIP BETWEEN PSYCHOSOCIAL WORK ENVIRONMENT AND NURSES' PERFORMANCE, ON STUDIES THAT USED THE VALIDATED INSTRUMENT COPENHAGEN PSYCHOSOCIAL QUESTIONNAIRE (COPSOQ): AN EMPTY SCOPING REVIEW.

Journal: Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

Published: September 27, 2023

Editorial: Psychosocial work environment during the COVID-19 pandemic.

Editorial: Psychosocial work environment during the COVID-19 pandemic.

Journal: Frontiers in public health

Published: August 03, 2023

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.

Journal: Cancers

Published: February 22, 2023

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer.

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer.

Journal: Cancers

Published: April 26, 2022

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer.

Journal: Frontiers in cell and developmental biology

Published: December 15, 2020

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 17, 2018

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Journal: Cancer chemotherapy and pharmacology

Published: March 21, 2017

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 26, 2016

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

Journal: British journal of cancer

Published: October 25, 2016

Showing 1-12 of 26

Last Updated: 09/26/2026